ALMOTRIPTAN MALATE

Post-LOE

almotriptan malate

Teva

ANDAORALTABLET

Approved

Jul 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

ALMOTRIPTAN MALATE (almotriptan malate) by Teva is 5-ht 1d , 5-ht 1b , and 5-ht 1f receptors. Approved for cluster headache () 1, migraine, migraine and 1 more indications. First approved in 2015.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

5-HT 1D , 5-HT 1B , and 5-HT 1F receptors. Almotriptan has weak affinity for 5-HT 1A and 5-HT 7 receptors, but has no significant affinity or pharmacological activity at 5-HT 2 , 5-HT 3 , 5-HT 4 , 5-HT 6 ; alpha or beta adrenergic; adenosine (A 1 , A 2 ); angiotensin (AT 1 , AT 2 ); dopamine (D 1 ,…

Indications (3)

cluster headache () 1 migraine

Worked on ALMOTRIPTAN MALATE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT00257010Phase 3Completed

A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

Started Dec 2005

447 enrolled

Migraine

NCT00210483Phase 3Completed

A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents

Started Jul 2003

866 enrolled

Migraine